Arrowhead Pharmaceuticals
ARWRPharmaPasadena, California, United States · Est. 1989
Arrowhead Pharmaceuticals is a biopharmaceutical company developing RNA interference therapeutics for treating diseases with high unmet medical needs.
8
Pipeline Programs↗
Distinct drugs in development (Preclinical–Phase 3)
9
Indications↗
Distinct diseases across all programs
65
Clinical Trials↗
All sponsored trials (all statuses)
5
Orange Book Patents
Across 1 drug with upcoming expirations
Pipeline
Pipeline Snapshot
By Phase
8 drugs in development
Phase 32
Phase 21
Phase 11
Preclinical4
By Therapeutic Area
top 3
Metabolic & Endocrine
556%
Respiratory
111%
Neurology
111%
R&D Momentum
54/100
Pipeline Velocity
22/100
Trial Completion Rate
58/100
Pipeline Concentration
38/100
Pipeline Freshness
82/100
Strategic Signals
- ↗Active in Respiratory but thin pipeline — potential licensing opportunity
Activity
Recent Activity
Last 14 days
Sep 19, 2026
Recruiting
A Phase 1/2a Placebo-Controlled Dose-Escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ARO-MAPT-SC in Healthy Subjects and Subjects With Early Alzheimer's Disease
Sep 16, 2026
Recruiting
A First-In-Human Dose-Escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Single and Multiple Doses of ARO-033 in Adult Participants
Sep 15, 2026
Terminated
A Phase 1/2a Study Evaluating the Effects of ARO-MUC5AC Inhalation Solution in Healthy Subjects and Patients With Muco-Obstructive Lung Disease
Earlier
Sep 3, 2026TrialDouble-Blind, Placebo-Controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Plozasiran in Adults With Severe Hypertriglyceridemia at High Risk of Acute Pancreatitis (SHASTA-5 Study)
Aug 19, 2026TrialA Phase 1/2a Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ARO-INHBE in Adult Volunteers With Obesity With and Without Diabetes Mellitus
Aug 19, 2026TrialPhase 1/2a, Double-blind, Placebo-controlled, Single and Multiple Dose-escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects of ARO-DIMERPA in Adult Subjects With Mixed Hyperlipidemia
Aug 13, 2026TrialA Phase 3 Open-Label Extension Study to Evaluate the Long-Term Safety and Efficacy of Plozasiran in Adults With Hypertriglyceridemia (SHASTA-10 Study)
Aug 13, 2026TrialPhase 3 Study to Evaluate the Efficacy and Safety of Zodasiran in Adolescent and Adult Subjects With Homozygous Familial Hypercholesterolemia (YOSEMITE)
4 more events
Aug 12, 2026TrialA Phase 1/2a Dose-Escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ARO-DUX4 (SRP-1001) in Adult Patients and Adolescent Patients With Facioscapulohumeral Muscular Dystrophy Type 1
Aug 12, 2026TrialA Phase 1/2a Dose-Escalating Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ARO-DM1 (SRP-1003) in Subjects With Type 1 Myotonic Dystrophy Who Are ≥18 to ≤ 65 Years
Aug 7, 2026TrialDouble-blind, Placebo-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Plozsiran in Adults With Severe Hypertriglyceridemia
Aug 6, 2026TrialA Phase 1/2a Study Evaluating the Effects of ARO-MMP7 Inhalation Solution in Healthy Subjects and Patients With Idiopathic Pulmonary Fibrosis
Details
Company Info
Company Overview
—
Mkt Cap
—
Revenue
—
Cash
CEOVipin Nair
Founded1989
HQPasadena, California, United States
Websitearrowheadresearch.com
LinkedInCompany Page
Therapeutic Focus
Infectious DiseaseImmunologyOncologyNeurologyOtherMetabolic & EndocrineRespiratory
Pipeline
Drug Pipeline
Indication
Preclinical
Phase 1
Phase 2
Phase 3
Approved
Metabolic & Endocrine
Neurology
Metabolic & Endocrine
Hyperlipidemia; Mixed
ARO-DIMERPAPreclinical
Hypertriglyceridemia
RedemploPhase 3
Neurology
Alzheimer Disease
ARO-MAPT-SCPreclinical
Unknown / Other
Regulatory
Regulatory Timeline
20252 events
FDANov 18
Redemplo — REDEMPLO
Application NDA219947 (NDA)
FDANov 18
Redemplo — REDEMPLO
Application NDA219947 (NDA)
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)